NoeticInsight

11/03/2025

👉With its ability to analyze large data sources and use deep learning to gain insights, AI has the potential to drastically expedite drug discovery. Now, AI may even be able to discover disease biomarkers and analyze electronic health record (EHR) data to find potential candidates for clinical trials.

📌If you’re looking for a partner to help dig through clinical insights, reach out to us! https://hubs.li/Q03Rh_4L0

10/31/2025

👉In the MARIPOSA trial, 3-year overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC was 60% compared to 51% in the patient population receiving osimertinib.

📌Want to know how clinical trials will affect the market and prescribing patterns? Learn more about our services: https://hubs.li/Q03QR5jv0


Source: https://hubs.li/Q03QR5T40

10/29/2025

In a fast-moving market, staying ahead means being faster, smarter, and more connected.

That’s where NoeticInsight comes in. From rapid research to real-time testing, we help pharma teams make confident decisions backed by expert input and timely data.

Read to learn more? Let’s connect: https://hubs.li/Q03L9M2w0

10/28/2025

📌PRIMO creates a place for exchanging insights and key developments about the latest cancer innovations with attendees including faculty, US practicing clinicians, decision makers, and prescribers.

Contact us to learn more about PRIMO Summits! https://hubs.li/Q03N9kYw0

10/27/2025

🌍 The global healthcare market is expanding fast, with projections showing growth from $11.9T in 2022 to $15.8T by 2025. What’s fueling it? Innovation, shifting demographics, and rising chronic conditions.

As the landscape evolves, informed decisions matter more than ever. We help pharma teams stay ahead by connecting you with real-world expert perspectives and strategic market intelligence, so they can adapt, respond, and lead with clarity.

📖 Explore how research is shaping the future of healthcare: https://hubs.li/Q03L9JKQ0

Discover how healthcare market research empowers pharmaceutical marketers with insights and strategies for navigating an evolving industry landscape.

10/23/2025

📍 Real-time insights from the congress floor.

When your team is attending a congress like EAHAD, speed matters. NoeticInsight helps you capture expert feedback as the data is being presented, not weeks later. Pharma teams can engage HCPs and KOLs in the moment and develop actionable insights while conversations are still fresh. Whether you're refining your strategy or planning your next move, we help you stay ahead.

Learn more: https://hubs.li/Q03L9CWy0

10/16/2025

When it comes to aggressive cancers, every extra moment matters. That’s why the results of a new Mayo Clinic study are turning heads.

In a first-of-its-kind trial, researchers explored a novel approach to treating glioblastoma in patients 65+, using short-course hypofractionated proton beam therapy paired with advanced imaging. The result? Significantly improved survival in a population that typically faces few effective options.

This breakthrough offers not just renewed hope for patients but also critical insights for clinicians navigating a complex treatment landscape.

Explore what it could mean for future care decisions and clinical strategy:
https://hubs.li/Q03LwHfB0

10/14/2025

🔍 Phase 3 clinical trials test the effectiveness and safety of a new treatment against the current standard of care. These trials are a critical point of the journey as treatments proceed to seeking FDA approval.

⭐For your questions about the future of treatment patterns and effect of new approvals, Noetic Insight has you covered. Learn more at https://hubs.li/Q03N8WLl0

10/13/2025

Why do our experts choose to work with NoeticInsight? 🧐

Our participating physicians tell us they value the opportunity to stay informed, gain visibility into emerging treatments, and see what pharma leaders think about the future of care. At NoeticInsight, we create space for two-way insight so that pharma teams can gain clarity, and HCPs can stay engaged and empowered.

Learn more about our mission and services: https://hubs.li/Q03L9n9p0

10/09/2025

In our intelligence report, oncology specialists share real-world reactions to the PROpel trial results. Here's a peek at what experts concluded:

🔹 50% believe PROpel established PARP inhibitors as the standard of care for HRRm-positive mCRPC
🔹 30% cite concerns about real-world tolerability of olaparib + abiraterone
🔹 30% believe that the efficacy in the BRCAm subgroup could have driven all-comers efficacy

Download the full report to gain expert insights that could shape your strategy: https://hubs.li/Q03L9dB20

NoeticInsight: Expert insights on NSCLC treatments. Get intelligence reports to guide your oncology strategy. Real-time clinical expertise.